leisure time -WSS

leisure time

author：entertainment 2025-09-28 02:47:18 - browse：8374

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： 4 missing after record

focus

WSS

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

Men with early prostate cancer can safely opt out of treatment

How a key Senate committee is planning to regulate PBMs

Doctors increasingly discourage vaping amid mounting health concerns

Sophia Smith scores twice for US in in 3

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Russian and Belarusian players banned from a women's tennis tournament in Prague

Heart attack and stroke risk calculators need revising

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

New air purifier tech could be key to improving indoor air quality

Statins reduce cardiovascular risk in people living with HIV

Continuity nursing helped my family in our darkest PICU moments

Russian and Belarusian players banned from a women's tennis tournament in Prague

Medicare details structure of new drug price negotiation program

My chronic pain journey would have been easier knowing 5 things % STAT

hotspot

Judge orders hearing on Trump's motion to disqualify Fulton County DA

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

'Weather

Men with early prostate cancer can safely opt out of treatment

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

Men with early prostate cancer can safely opt out of treatment

hotspot

focus

focus

focus